|
Name: 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)
Type: Psychedelic phenethylamine
AKA: 2C-I
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
2C-I, a synthetic phenethylamine, was developed in the 1970s by Alexander Shulgin. It is known for its psychedelic effects and has been used in research and recreational contexts. Its history reflects ongoing interest in psychedelic research and regulation.
|
|
V. Legal Information
2C-I, a psychedelic compound, is often regulated under analog laws due to its psychoactive effects. Its legal status varies by jurisdiction.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
2C-I is a psychedelic compound that produces hallucinogenic effects. As an upper, it induces altered perception and euphoria. Short-term effects include visual and auditory distortions, while long-term use may lead to psychological issues. Overdose risks involve severe agitation and hallucinations. Safe use involves cautious dosing, and recent research emphasizes its effects and potential risks.  |
|
VII. Psychological Effects
2C-I, a psychedelic, affects serotonin receptors, leading to altered perception and cognition. Immediate effects include euphoria and hallucinations, lasting several hours. Long-term use can cause persistent changes in perception and mood swings. Recent research indicates risks of psychological disturbances with frequent use.
 |
|
VIII. Culture
2C-I is a psychedelic phenethylamine causing altered perception and hallucinations, classifying it as neither an upper nor a downer. Short-term use induces euphoria, visual distortions, and altered consciousness, while long-term use is not well-documented. Overdose can result in severe agitation, confusion, and cardiovascular issues. Safe dosages are not well-established, with lower doses advised. Recent research focuses on its psychotropic effects and potential therapeutic uses. Physical signs include dilated pupils, increased heart rate, and elevated blood pressure.
 |